The ROAR trial tested the hypothesis that returning familial hypercholesterolemia-associated genetic results leads to ...
The Crawford otolaryngology research fellowship at Mayo Clinic in Florida is geared toward U.S. medical school graduates and early-career otolaryngologists who were trained outside the U.S.
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial. Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101. PRINCETON, N.J., J ...
MoonLake regains momentum after the FDA Type B meeting allows BLA submission for sonelokimab in HS without additional trials.
People with hepatitis C virus who inject drugs could be evaluated for cure approximately 2 months earlier than current ...
For further information on the two studies, please see Biofrontera’s press releases 3,4 from September 16, 2025, and August 25, 2025. The 1-year follow-up phase of the phase III study on AK is still ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the ...
The Centers for Disease Control and Prevention upended the childhood vaccine schedule Monday, reducing the number of ...
Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback